The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)
 
Radka Obermannova
Consulting or Advisory Role - Amgen; Bayer; Roche
Speakers' Bureau - Amgen; Lilly; Roche
Research Funding - Merck
 
Gyorgy Bodoky
Consulting or Advisory Role - Bayer; Ipsen; Janssen; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Janssen; Lilly; Novartis; Pfizer; Roche
 
Jana Prausová
No Relationships to Disclose
 
Rocio Garcia-Carbonero
Honoraria - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CELGENE (I); IPSEN; Lilly (I); MERCK; Merck (I); MSD; MSD (I); Novartis; Novartis (I); PFIZER; Pfizer (I); ROCHE; Roche (I); SERVIER
Consulting or Advisory Role - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb (I); IPSEN; Lilly (I); Merck Sharp & Dohme (I); MSD; Novartis (I); Pfizer (I); Roche (I)
Research Funding - PFIZER
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim (I); Ipsen; Lilly (I); Merck; Novartis; Pfizer; Pfizer (I); Roche; Roche (I); Sanofi
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Teva
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Ipsen; Ipsen (I); Janssen (I); Merck; Pfizer; Pfizer (I); Sanofi; Servier
 
Pilar Garcia Alfonso
No Relationships to Disclose
 
David Craig Portnoy
Employment - CNS Healthcare (I)
Research Funding - Lilly
 
Allen Lee Cohn
Honoraria - Bristol-Myers Squibb; Merrimack; Roche/Genentech
Speakers' Bureau - Merrimack
 
Eric Van Cutsem
Consulting or Advisory Role - Bayer; Lilly; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Philip Clingan
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Tae Won Kim
Consulting or Advisory Role - Amgen
Research Funding - Bayer; Roche
 
Sameera R. Wijayawardana
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Rebecca Hozak
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Federico Nasroulah
Employment - Lilly/ImClone
Stock and Other Ownership Interests - Lilly/ImClone
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda